163 related articles for article (PubMed ID: 23147412)
1. Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.
Somnay Y; Simon K; Harrison AD; Kunnimalaiyaan S; Chen H; Kunnimalaiyaan M
Anticancer Drugs; 2013 Jan; 24(1):66-72. PubMed ID: 23147412
[TBL] [Abstract][Full Text] [Related]
2. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
[TBL] [Abstract][Full Text] [Related]
3. MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition.
Burke JF; Schlosser L; Harrison AD; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2013 Nov; 20(12):3862-8. PubMed ID: 23900743
[TBL] [Abstract][Full Text] [Related]
4. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors.
Pitt SC; Chen H; Kunnimalaiyaan M
Ann Surg Oncol; 2009 Oct; 16(10):2936-42. PubMed ID: 19588205
[TBL] [Abstract][Full Text] [Related]
6. MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype.
Chen JY; Cook MR; Pinchot SN; Kunnimalaiyaan M; Chen H
J Surg Res; 2010 Jan; 158(1):15-9. PubMed ID: 19765735
[TBL] [Abstract][Full Text] [Related]
7. Hemiasterlin derivative (R)(S)(S)-BF65 and Akt inhibitor MK-2206 synergistically inhibit SKOV3 ovarian cancer cell growth.
Lai WT; Cheng KL; Baruchello R; Rondanin R; Marchetti P; Simoni D; Lee RM; Guh JH; Hsu LC
Biochem Pharmacol; 2016 Aug; 113():12-23. PubMed ID: 27328368
[TBL] [Abstract][Full Text] [Related]
8. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.
Agarwal E; Chaudhuri A; Leiphrakpam PD; Haferbier KL; Brattain MG; Chowdhury S
BMC Cancer; 2014 Mar; 14():145. PubMed ID: 24581231
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells.
Pitt SC; Chen H; Kunnimalaiyaan M
J Am Coll Surg; 2009 Jul; 209(1):82-8. PubMed ID: 19651067
[TBL] [Abstract][Full Text] [Related]
11. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab.
Iida M; Brand TM; Campbell DA; Starr MM; Luthar N; Traynor AM; Wheeler DL
Cancer Biol Ther; 2013 Jun; 14(6):481-91. PubMed ID: 23760490
[TBL] [Abstract][Full Text] [Related]
12. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.
Li Z; Yan S; Attayan N; Ramalingam S; Thiele CJ
Clin Cancer Res; 2012 Jul; 18(13):3603-15. PubMed ID: 22550167
[TBL] [Abstract][Full Text] [Related]
13. Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids.
Somnay YR; Dull BZ; Eide J; Jaskula-Sztul R; Chen H
Cancer Gene Ther; 2015 Oct; 22(10):496-505. PubMed ID: 26403073
[TBL] [Abstract][Full Text] [Related]
14. Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells.
Zitzmann K; Ailer G; Vlotides G; Spoettl G; Maurer J; Göke B; Beuschlein F; Auernhammer CJ
Int J Oncol; 2013 Dec; 43(6):1824-32. PubMed ID: 24100469
[TBL] [Abstract][Full Text] [Related]
15. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors.
Gloesenkamp CR; Nitzsche B; Ocker M; Di Fazio P; Quint K; Hoffmann B; Scherübl H; Höpfner M
Int J Oncol; 2012 Mar; 40(3):876-88. PubMed ID: 22075556
[TBL] [Abstract][Full Text] [Related]
16. Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines.
Larsson DE; Hassan S; Larsson R; Oberg K; Granberg D
Cancer Chemother Pharmacol; 2009 Dec; 65(1):5-12. PubMed ID: 19381631
[TBL] [Abstract][Full Text] [Related]
17. Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma.
Knowles JA; Golden B; Yan L; Carroll WR; Helman EE; Rosenthal EL
Laryngoscope; 2011 Nov; 121(11):2359-65. PubMed ID: 22020886
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM
Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665
[TBL] [Abstract][Full Text] [Related]
19. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms.
Zitzmann K; Vlotides G; Brand S; Lahm H; Spöttl G; Göke B; Auernhammer CJ
Endocr Relat Cancer; 2012 Jun; 19(3):423-34. PubMed ID: 22499437
[TBL] [Abstract][Full Text] [Related]
20. The molecular pathogenesis and management of bronchial carcinoids.
Cakir M; Grossman A
Expert Opin Ther Targets; 2011 Apr; 15(4):457-91. PubMed ID: 21275849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
